Multiple sclerosis (MS) is a progressive, chronic, immune-system-related disease of the central nervous system, usually diagnosed in young adults with more than 2.3 million people worldwide. It is the most common neurological disease in young and middle-aged adults resulting in physical disability, inability to work or early retirement, significantly impaired quality of life and a substantial burden on society in terms of associated costs as the disease progresses. MS is characterized by a variety of symptoms, the most common being difficulty moving, spasticity, fatigue, sensory deficits, palsy, pain, bladder dysfunction, cognitive dysfunction, depression and visual impairment.
About 80% of patients suffer from MS-associated spasticity during the course of their disease. Of these, a substantial proportion is dissatisfied with the limited efficacy of classical oral antispasticity medications at tolerable doses. For these patients, THC-CBD spray has been shown to be a promising option. Through its action via the endocannabinoid pathway, it might help patients who have not responded adequately to more mainstream medications and might even lead to a reduction of overall medications and associated adverse events.
Efficacy of THC-CBD oromucosal spray has been supported in randomized, controlled clinical studies and its effectiveness confirmed in observational studies. It shows alleviation of symptoms together with improvement of daily activities and improvement in quality of life for patients. In addition,THC-CBD spray has been shown to have a good safety profile and is generally well tolerated, especially in comparison with mainstream medications.